Core Viewpoint - Rosen Law Firm is encouraging investors of Telix Pharmaceuticals Ltd. to secure legal counsel before the January 9, 2026 deadline for a securities class action lawsuit related to the company's performance during the specified class period [1][2]. Group 1: Class Action Details - The class period for the securities class action is from February 21, 2025, to August 28, 2025 [1]. - Investors who purchased Telix securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 9, 2026 [3]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Allegations Against Telix Pharmaceuticals - The lawsuit alleges that Telix's defendants made materially false and misleading statements regarding the progress of prostate cancer therapeutic candidates and the quality of its supply chain [5]. - It is claimed that these misrepresentations led to damages for investors when the true information became public [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Nidec Corporation due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Allegations - Nidec Corporation is facing scrutiny following a report of improper accounting practices linked to its management, which led to a significant drop in its stock price [3]. - On September 4, 2025, Nidec's American Depositary Receipts (ADRs) fell by 22.7% after the announcement of the probe into accounting issues [3]. Group 2: Class Action Information - Shareholders who purchased Nidec Corporation securities may be eligible for compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. - Interested investors can join the class action by submitting a form or contacting the Rosen Law Firm directly for more information [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Skye Bioscience, Inc. securities between November 4, 2024, and October 3, 2025, due to alleged misleading statements regarding the company's business and product effectiveness [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Skye Bioscience made materially false and misleading statements about its product nimacimab, asserting that it was less effective than represented, which overstated its clinical and commercial prospects [5]. - Investors who purchased Skye securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by January 16, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Inspire Medical Systems, Inc. to secure legal counsel before the January 5, 2026 deadline for a class action lawsuit related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - The class period for the Inspire Medical Systems, Inc. stock is from August 6, 2024, to August 4, 2025, inclusive [2]. - Investors who purchased common stock during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by January 5, 2026 [4]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience [5]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [5]. Group 3: Case Allegations - The lawsuit alleges that Inspire Medical misrepresented key facts about its Inspire V sleep apnea device, including market demand and necessary steps for its launch [6]. - Defendants are accused of issuing materially false and misleading statements that led investors to believe in strong demand for the device, resulting in investor damages when the truth was revealed [6].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Freeport-McMoRan Inc. securities between February 15, 2022, and September 24, 2025, alleging misleading statements and safety issues at the Grasberg Block Cave mine in Indonesia [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Freeport-McMoRan did not ensure adequate safety at its Grasberg Block Cave mine, leading to heightened risks for workers [5]. - It is alleged that the company failed to disclose these risks, which included regulatory, litigation, and reputational risks, resulting in materially false and misleading statements about its business and operations [5]. - Investors are encouraged to join the class action, with the deadline to serve as lead plaintiff set for January 12, 2026 [1][3]. Group 2: Investor Guidance - Investors who purchased Freeport-McMoRan securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [4].

Core Points - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Western Alliance Bancorporation due to allegations of materially misleading business information [1] - A class action is being prepared by Rosen Law Firm to seek recovery of investor losses without any out-of-pocket fees for those who purchased Western Alliance Bancorporation securities [2] - Western Alliance Bancorporation's stock fell by 10.88% on October 16, 2025, following the disclosure of a lawsuit against Cantor Group V LLC for fraud related to collateral loans [3] Company Background - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4] - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4]

Core Viewpoint - Rosen Law Firm is reminding investors of WPP plc to secure legal counsel before the December 8, 2025 deadline for a securities class action related to the purchase of American Depositary Shares (ADS) during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased WPP ADSs between February 27, 2025, and July 8, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by December 8, 2025 [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Case Allegations - The complaint alleges that WPP provided misleading statements about its media arm's capabilities, failing to address significant market share losses and macroeconomic challenges, which led to investor damages when the truth was revealed [5].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Freeport-McMoRan Inc. securities between February 15, 2022, and September 24, 2025, alleging misleading statements and safety issues at the Grasberg Block Cave mine in Indonesia [2][6]. Group 1: Lawsuit Details - The lawsuit claims that Freeport-McMoRan failed to ensure adequate safety at its Grasberg Block Cave mine, leading to heightened risks for workers [6]. - It is alleged that the company's statements regarding its business operations and prospects were materially false and misleading due to undisclosed risks [6]. - Investors who purchased securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. Group 2: Next Steps for Investors - Investors wishing to join the class action must move the Court by January 12, 2026, to serve as lead plaintiff [4]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [4][7]. - It is noted that no class has been certified yet, and investors are encouraged to select qualified counsel with a successful track record [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a class action lawsuit related to securities purchased between July 26, 2024, and September 17, 2025 [2][3]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which rendered them less reliable and posed health risks to users [6]. - The defendants are accused of making false statements regarding the reliability and functionality of the G6 and G7 devices, leading to increased regulatory scrutiny and potential financial harm [6]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - Rosen Law Firm has a history of successful settlements in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [5]. - The firm has been recognized for its leadership in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [5].

Core Viewpoint - A new securities class action lawsuit has been filed against CarMax, Inc., expanding the class period to include investors who acquired CarMax securities between June 20, 2025, and November 5, 2025, following significant market reactions to the company's leadership changes and financial disclosures [1][2][3]. Group 1: Class Action Details - The expanded class period now includes investors affected by the announcement of CEO Bill Nash's termination, which led to a share price drop of $9.48, or 23%, on November 6, 2025 [2]. - The lawsuit focuses on allegations that CarMax misled investors regarding its business model and growth prospects, particularly in light of its Q1 2026 earnings claims [3][4]. Group 2: Financial Performance - On June 20, 2025, CarMax reported a double-digit EPS growth for Q1 2026, claiming a strong market position, but the lawsuit alleges this was misleading as it did not account for consumers pulling forward purchases to avoid tariffs [4]. - CarMax's Q2 2026 results revealed a 24% year-over-year decline in net EPS, a 5.4% drop in retail used unit sales, and a 6.3% decrease in comparable store used unit sales [5]. - Concerns were raised about the quality of CarMax's Auto Finance loan portfolio, with an 11.02% revenue decline attributed to a $142 million loan loss provision, marking a nearly 40% sequential increase and a 24% year-over-year rise [6]. Group 3: Market Reaction and Analyst Commentary - Following the CEO's termination, analysts expressed concerns that the situation indicated deeper issues within CarMax, shifting perceptions from a value play to a potential "falling knife" scenario [7].